Logo

Calliditas Receives the US FDA's Fast Track Designation for Setanaxib to Treat Primary Biliary Cholangitis

Share this

Calliditas Receives the US FDA's Fast Track Designation for Setanaxib to Treat Primary Biliary Cholangitis

Shots:

  • The US FDA has granted FTD to selinexor (NOX inhibitor) for the treatment of PBC. Additionally- the therapy has previously received ODD for PBC in the US & EU
  • The P-II clinical trial of the therapy demonstrated anti-fibrotic activity as measured by Fibroscan and showed favorable tolerability profile along with the impact on fatigue
  • The company plans to start P-II/III study for PBC in H2’21 based on results from the P-I study which evaluated higher doses of setanaxib in healthy volunteers

| Ref: Calliditas | Image: Calliditas

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions